MedTrace Logo

Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

NCT06257693 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2026-02-27

No results posted yet for this study

Summary

The study is to assess whether the Enolen is safe and delivers anti-androgen medication locally in patients that are planning for radical prostatectomy.

Conditions

  • Prostate Adenocarcinoma

Interventions

DRUG

enzalutamide

Localized single delivery of the Enolen implant (polymer + enzalutamide) with planned radical prostatectomy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Alessa Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Peter Pinto, MD · National Cancer Institute (NCI)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-21
Primary Completion
2028-06-30
Completion
2028-08-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06257693 on ClinicalTrials.gov